🎉 M&A multiples are live!
Check it out!

Puma Biotechnology Valuation Multiples

Discover revenue and EBITDA valuation multiples for Puma Biotechnology and similar public comparables like Pharming, Vivoryon Therapeutics, and Galapagos.

Puma Biotechnology Overview

About Puma Biotechnology

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.


Founded

2007

HQ

United States of America
Employees

172

Financials

LTM Revenue $227M

LTM EBITDA n/a

EV

$118M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Puma Biotechnology Financials

Puma Biotechnology has a last 12-month revenue of $227M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Puma Biotechnology achieved revenue of $230M and an EBITDA of $48.1M.

Puma Biotechnology expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Puma Biotechnology valuation multiples based on analyst estimates

Puma Biotechnology P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $236M $230M XXX XXX XXX
Gross Profit $173M $173M XXX XXX XXX
Gross Margin 73% 75% XXX XXX XXX
EBITDA $47.5M $48.1M XXX XXX XXX
EBITDA Margin 20% 21% XXX XXX XXX
Net Profit $2K $21.6M XXX XXX XXX
Net Margin 0% 9% XXX XXX XXX
Net Debt $22.1M $15.1M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Puma Biotechnology Stock Performance

As of April 15, 2025, Puma Biotechnology's stock price is $3.

Puma Biotechnology has current market cap of $145M, and EV of $118M.

See Puma Biotechnology trading valuation data

Puma Biotechnology Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$118M $145M XXX XXX XXX XXX $0.56

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Puma Biotechnology Valuation Multiples

As of April 15, 2025, Puma Biotechnology has market cap of $145M and EV of $118M.

Puma Biotechnology's trades at 0.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Puma Biotechnology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Puma Biotechnology and 10K+ public comps

Puma Biotechnology Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $118M XXX XXX XXX
EV/Revenue 0.5x XXX XXX XXX
EV/EBITDA 2.5x XXX XXX XXX
P/E 4.8x XXX XXX XXX
P/E/Growth -0.3x XXX XXX XXX
EV/FCF 3.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Puma Biotechnology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Puma Biotechnology Valuation Multiples

Puma Biotechnology's NTM/LTM revenue growth is -3%

Puma Biotechnology's revenue per employee for the last fiscal year averaged $1.3M, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Puma Biotechnology's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Puma Biotechnology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Puma Biotechnology and other 10K+ public comps

Puma Biotechnology Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -2% XXX XXX XXX XXX
EBITDA Margin 21% XXX XXX XXX XXX
EBITDA Growth 1% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 18% XXX XXX XXX XXX
Revenue per Employee $1.3M XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 35% XXX XXX XXX XXX
R&D Expenses to Revenue 24% XXX XXX XXX XXX
Opex to Revenue 59% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Puma Biotechnology Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Puma Biotechnology M&A and Investment Activity

Puma Biotechnology acquired  XXX companies to date.

Last acquisition by Puma Biotechnology was  XXXXXXXX, XXXXX XXXXX XXXXXX . Puma Biotechnology acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Puma Biotechnology

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Puma Biotechnology

When was Puma Biotechnology founded? Puma Biotechnology was founded in 2007.
Where is Puma Biotechnology headquartered? Puma Biotechnology is headquartered in United States of America.
How many employees does Puma Biotechnology have? As of today, Puma Biotechnology has 172 employees.
Who is the CEO of Puma Biotechnology? Puma Biotechnology's CEO is Mr. Alan H. Auerbach.
Is Puma Biotechnology publicy listed? Yes, Puma Biotechnology is a public company listed on NAS.
What is the stock symbol of Puma Biotechnology? Puma Biotechnology trades under PBYI ticker.
When did Puma Biotechnology go public? Puma Biotechnology went public in 2012.
Who are competitors of Puma Biotechnology? Similar companies to Puma Biotechnology include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Puma Biotechnology? Puma Biotechnology's current market cap is $145M
What is the current revenue of Puma Biotechnology? Puma Biotechnology's last 12-month revenue is $227M.
What is the current EV/Revenue multiple of Puma Biotechnology? Current revenue multiple of Puma Biotechnology is 0.5x.
What is the current revenue growth of Puma Biotechnology? Puma Biotechnology revenue growth between 2023 and 2024 was -2%.
Is Puma Biotechnology profitable? Yes, Puma Biotechnology is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.